ع
Defense Secretary Pete Hegseth unveiled the screening programme in a video posted to X on July 15, 2026, under the caption “High-T Department,” framing it as a way to verify that troops maintain appropriate hormone levels for peak performance. Hegseth stated that the military owes its service members the best medical care available and that the initiative meets that standard by promoting strength and resilience both during and after their careers. Pentagon spokesman Sean Parnell issued a statement confirming that the protocol takes effect immediately for all active-duty and reserve personnel aged 30 and older, establishing a baseline to support a healthy and dominant fighting force through targeted therapy where needed. Taking testosterone for non-medical reasons such as muscle enhancement remains strictly prohibited under existing rules, Parnell noted.
The screening forms part of annual health assessments and remains optional for those under 30, according to the announcement from Hegseth. Troops identified with low levels can opt for hormone replacement therapy, though Hegseth stressed the programme does not involve artificial enhancement. Democratic Senator Tammy Duckworth, an Iraq war veteran serving on the armed services committee, urged that hormone testing be made available to both men and women, while Congresswoman Chrissy Houlahan, a Pennsylvania Democrat and Air Force veteran, described the effort on X as Hegseth’s latest culture-war focus. The Pentagon offered no additional comment on whether female personnel would undergo testing or receive related evaluations for perimenopause.
Dr Mohit Khera, who chaired a US Food and Drug Administration expert panel last year on military screening and testosterone use, told the BBC that all men over 30 should undergo checks because the hormone serves as a key indicator of overall current and future health. Khera, a professor of urology at Baylor College of Medicine, explained that low testosterone can reduce muscle mass and energy, potentially creating disadvantages in combat situations, yet cautioned that replacement should only follow confirmed symptoms. Benefits of therapy include greater muscle mass, less fat accumulation, reduced depression risk and improved bone density over time, he added, while warning that treatment during reproductive years can cause infertility and carries a theoretical increase in cardiovascular risk.
A study of 796 male US soldiers and veterans published in the Journal of Military and Veterans’ Health found that mean total testosterone concentrations stood at 426.9 ng/dl, with 24.1 percent registering below 300 ng/dl under Endocrine Society guidelines and 17.2 percent classified as low according to US Army Medical Department age-adjusted standards. Research tracking US Army Rangers during training, detailed in the International Journal of Sports and Exercise Medicine, showed testosterone levels dropping 25 to 30 percent after a single night of sleep deprivation, with earlier analyses documenting declines of up to 65 percent during extended deployments and high-stress exercises. In 2017, fewer than 1 percent of military men under age 50 and 1.5 percent over that threshold received testosterone replacement therapy, with only 44.5 percent of those cases meeting clinical practice guidelines, according to a document compiled by the International Association of Fire Fighters that referenced Defense Department data.
A VA database analysis of more than 83,000 veterans aged 50 and older with low testosterone, conducted between 1999 and 2014, determined that restoring levels to normal through treatment correlated with lower risks of heart attack, stroke or death from any cause compared with those who remained untreated, the research team reported. Veterans frequently exhibit testosterone concentrations 20 to 30 percent below those of age-matched civilians, with symptoms emerging five to 10 years earlier, one analysis of post-service health outcomes indicated. These patterns underscore challenges posed by military lifestyles, including disrupted sleep, physical strain and environmental stressors that studies have repeatedly linked to hormone suppression.
The initiative coincides with broader administration efforts to expand access to testosterone therapy, as Health Secretary Robert F Kennedy Jr has promoted it as a response to national fertility concerns, according to multiple reports on policy shifts. In June 2026, the Department of Health and Human Services requested class-wide updates to testosterone product labeling that remove the prior limitation stating safety and effectiveness remain unestablished for age-related hypogonadism, while revising warnings on prostate cancer and benign prostatic hyperplasia following review of the TRAVERSE clinical trial and related ambulatory blood pressure studies, an HHS announcement stated. The changes reflect a reassessment of evidence that had previously restricted prescribing, though officials continue to recommend patient screening and ongoing monitoring before and during treatment.
